Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with ...
Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer. Initial focus on patient selection, treatment planning and ...
Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto to include ...
A PSMA PET scan found more recurrent prostate cancer at low PSA levels than a standard scan, helping guide more potentially curative treatment decisions. A newer type of prostate cancer scan called 64 ...
The main market opportunities lie in PSMA-targeted therapies and radiodiagnostics, which are proving commercially successful for PET imaging and treatment of prostate cancer. Growth potential exists ...
BERLIN--(BUSINESS WIRE)-- Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary ...
Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all other treatment options, a new study now demonstrates that the therapy is ...
Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...
A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...
Surgery patients staged with PSMA-PET appear to have a lower risk of early BCR than those staged with conventional imaging. Early oncologic outcomes after radical prostatectomy (RP) for very high risk ...
Novartis announces new PSMAddition data shows 58% lower risk of PSA progression with Pluvicto in metastatic hormone-sensitive prostate cancer: Basel Tuesday, May 19, 2026, 16:00 H ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results